Laboratory Workup for Suppressed TSH (0.2 µIU/mL) Without Symptoms
Order free T4 and free T3 (or total T3) immediately to distinguish between subclinical hyperthyroidism and overt hyperthyroidism, as this determines both prognosis and management. 1
Initial Laboratory Studies
When TSH is suppressed below the lower limit of normal (typically <0.4 mIU/L), the following algorithmic approach should be followed:
Step 1: Confirm and Characterize the Thyroid Dysfunction
Free T4 (FT4): Essential to assess the biological severity of thyrotoxicosis 1
- If FT4 is elevated with low TSH → confirms overt hyperthyroidism
- If FT4 is normal → proceed to next step
Free T3 or Total T3: Required when FT4 is normal 1
- Distinguishes T3-toxicosis from subclinical hyperthyroidism
- T3 may be the only elevated hormone in early disease or autonomous nodules 2
Step 2: Repeat Testing for Confirmation
Timing depends on clinical context:
- If patient has cardiac disease, atrial fibrillation, or serious medical conditions: repeat within 2 weeks 3
- If no concerning features: repeat within 3 months 3
- TSH <0.1 µIU/L warrants repeat testing within 4 weeks 3
Critical Pitfalls to Exclude
Before proceeding with extensive workup, rule out assay interference and non-thyroidal causes of low TSH 1:
Assay Interference (Box 1 from guidelines):
- Biotin supplementation (causes falsely low TSH and high thyroid hormones) 1
- Heterophile antibodies
- Anti-streptavidin antibodies
- Endogenous anti-TSH antibodies
Medications and Conditions Causing Low TSH:
- Dopamine infusions 4
- Pharmacologic glucocorticoids 4
- Subcutaneous octreotide 4
- Oral bexarotene 4
- Recovery phase from nonthyroidal illness 4
- First trimester pregnancy (physiologic) 4
When Results Show Persistent Subclinical Hyperthyroidism
If repeat testing confirms TSH <0.4 µIU/mL with normal FT4 and T3, additional etiologic workup is indicated 2, 3:
Etiologic Studies:
Radioactive iodine uptake (RAIU) and scan 2, 3
- Distinguishes hyperthyroidism (elevated/normal uptake) from thyroiditis (near-absent uptake)
- Identifies Graves' disease vs. toxic nodular goiter vs. toxic adenoma
- Do not perform if pregnant
Thyroid ultrasound: If nodularity is present on examination 2
TSH receptor antibodies (TRAb): If Graves' disease is suspected clinically
Special Considerations for TSH 0.2 µIU/mL
A TSH of 0.2 µIU/mL falls in the "low but detectable" range (0.1-0.4 µIU/L) 3. This level:
- Requires confirmation with repeat testing
- May represent early subclinical hyperthyroidism
- Could normalize spontaneously, particularly in elderly patients 4
- Warrants 3-12 month monitoring intervals if confirmed and patient remains asymptomatic without cardiac disease 3
When to Consider Rare Causes
If TSH is suppressed but FT4 and T3 are elevated with TSH remaining normal or elevated, consider 2:
- TSH-secreting pituitary adenoma (check alpha-subunit, obtain pituitary MRI)
- Thyroid hormone resistance (check family history, genetic testing for T3-receptor mutations)
- Assay interference from heterophile antibodies
Risk Stratification Laboratory Studies
For confirmed subclinical hyperthyroidism, consider additional studies based on risk factors 3, 5:
- ECG: Screen for atrial fibrillation (especially if age >60 years)
- Bone density (DEXA): For postmenopausal women (increased fracture risk)
- Cardiac evaluation: If patient has underlying heart disease
The key distinction is that asymptomatic patients with TSH 0.2 µIU/mL and normal thyroid hormones have subclinical hyperthyroidism, which carries different risks than overt disease—particularly for cardiovascular events and bone loss in specific populations. 3, 5